Clinical trials: sponsored by H. Lundbeck A/S
Dravet Syndrome
Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
To investigate the long-term safety and tolerability of clobazam when administered for 1 year as adjunctive therapy in paediatric patients aged ≥1 to ≤16 years with Dravet Syndrome.
- Trial name
- NCT02187809
- Testing
- Clobazam
- Where
- 9 sites in United States, Mexico
- Volunteers
- 3 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Brexpiprazole in Patients With Schizophrenia
To determine the safety and efficacy of brexpiprazole during long-term treatment.
- Trial name
- NCT01810783
- Testing
- Brexpiprazole
- Where
- 48 sites in United States, Estonia and 6 more
- Volunteers
- 210 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Aripiprazole Once-monthly in Patients With Schizophrenia
To obtain information on the safety, tolerability and effectiveness of aripiprazole once-monthly in a manner consistent with its intended use in everyday clinical practice in patients with schizophrenia who completed Study 14724A…
- Trial name
- NCT01959035
- Testing
- Aripiprazole once-monthly
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia
To assess the effectiveness of aripiprazole once-monthly in the maintenance treatment of patients with a diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text…
- Trial name
- NCT01795547
- Testing
- Aripiprazole and aripiprazole once-monthly, Paliperidone and paliperidone palmitate
- Where
- 2 sites in United States
- Volunteers
- 295 people
- Sponsor
- H. Lundbeck A/S
Stroke
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
The purpose of the study is to determine whether desmoteplase is effective and safe in the treatment of patients with acute ischaemic stroke when given within 3 to 9 hours from onset of stroke symptoms.
- Trial name
- NCT00856661
- Testing
- Desmoteplase
- Where
- 152 sites in United States, Belgium and 12 more
- Volunteers
- 270 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Anxiety Disorder
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder
The objective of the study is to evaluate the pharmacokinetics of vortioxetine and its metabolites in connection with multiple oral dosing in child and adolescent patients with a DSM-IV-TR diagnosis of Depressive or Anxiety…
- Trial name
- NCT01491035
- Testing
- Vortioxetine
- Where
- 7 sites in United States, Germany
- Volunteers
- 48 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Brexpiprazole in Patients With Acute Schizophrenia
To determine the efficacy and safety of brexpiprazole for the treatment of adults experiencing an acute episode of schizophrenia.
- Trial name
- NCT01810380
- Testing
- Brexpiprazole, Quetiapine extended release
- Where
- United States
- Volunteers
- 468 people
- Sponsor
- H. Lundbeck A/S
Post-traumatic Stress Disorder, PTSD
Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)
To evaluate the efficacy of brexpiprazole as adjunctive treatment to paroxetine (PAR) or sertraline (SER) on PTSD symptoms.
- Trial name
- NCT01987960
- Testing
- Brexpiprazole
- Where
- 59 sites in United States, Estonia and 7 more
- Volunteers
- 417 people
- Sponsor
- H. Lundbeck A/S
Alcohol Dependence
Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care
To determine the reduction in alcohol consumption in patients with alcohol dependence treated with 18 mg Selincro® as-needed use, in conjunction with continuous psychosocial support in primary care
- Trial name
- NCT02195817
- Testing
- Selincro® 18 mg with continuous psychosocial support: Cohort A, Initial psychosocial support: Cohort B
- Where
- 48 sites in France, Germany and 2 more
- Volunteers
- 378 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder
To assess the efficacy of acute treatment with 10 mg/day vortioxetine versus placebo on cognitive performance (focusing on the aspect concerning speed of processing, executive functioning, attention) in working patients with…
- Trial name
- NCT02279966
- Testing
- Vortioxetine 10 mg, Paroxetine 20 mg
- Where
- 18 sites in Estonia, Finland and 2 more
- Volunteers
- 152 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder
This study aims at evaluating the effect of vortioxetine on cognitive dysfunction in major depressive disorder (MDD) patients with inadequate response to current antidepressant treatment.
- Trial name
- NCT02272517
- Testing
- Vortioxetine 10-20 mg, Escitalopram 10-20 mg
- Where
- 16 sites in Finland, Germany and 2 more
- Volunteers
- 101 people
- Sponsor
- H. Lundbeck A/S
Alcohol Dependence
Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use
The purpose of this study is to explore the treatment effects of Selincro in alcohol dependent patients with liver impairment.
- Trial name
- NCT02197598
- Testing
- nalmefene
- Where
- 3 sites in Germany
- Volunteers
- 45 people
- Sponsor
- H. Lundbeck A/S
Insomnia
Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED)
The purpose of this trial is to study the safety of MK0928 on insomnia in the elderly.
- Trial name
- NCT00095043
- Testing
- MK0928, gaboxadol
- Volunteers
- 320 people
- Sponsor
- H. Lundbeck A/S
Bioequivalence
Bioequivalence Study of Idalopirdine in Healthy Subjects
The purpose of this study is to investigate whether 2 different tablet compositions are similar regarding absorption (uptake) in the body.
- Trial name
- NCT02894515
- Testing
- Idalopirdine commercial tablet (test), Idalopirdine clinical tablet (reference)
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia
The purpose of this study is to permit the patients with schizophrenia who received Sertindole during a previous randomised trial, study 99824, to continue with this treatment.
- Trial name
- NCT00763438
- Testing
- Sertindole
- Where
- France
- Volunteers
- 18 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Dose-finding Study With Lu AA24530 in Major Depressive Disorder
The primary purpose of this study is to assess the efficacy in treating patients with Major Depressive Disorder of one or more doses of Lu AA24530 relative to placebo
- Trial name
- NCT00599911
- Testing
- Lu AA24530, Duloxetine
- Where
- 72 sites in Australia, Austria and 15 more
- Volunteers
- 652 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Efficacy of Lu 31-130 in Patients With Schizophrenia
The main purpose with the study is to evaluate the efficacy and safety of Lu 31-130 in patients suffering from schizophrenia compared to placebo.
- Trial name
- NCT00768326
- Testing
- Zicronapine
- Where
- Germany
- Volunteers
- 280 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Cognition
Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia
The objective of this study is to explore the efficacy, safety and cognitive properties of Lu AE58054 as augmentation therapy to risperidone in patients with schizophrenia.
- Trial name
- NCT00810667
- Testing
- Lu AE58054
- Where
- 25 sites in Belgium, France and 6 more
- Volunteers
- 124 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Safety and Efficacy of Zicronapine in Patients With Schizophrenia
To assess the effect of zicronapine versus risperidone on metabolic parameters comprising body weight, body mass index (BMI), waist circumference, levels of fasting blood lipids and glucose during 6 months of treatment.
- Trial name
- NCT01295372
- Testing
- Zicronapine, Risperidone
- Where
- 24 sites in Czechia, Estonia and 3 more
- Volunteers
- 160 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder
The primary objective of this study was to compare the efficacy of escitalopram with that of duloxetine in outpatients with Major Depressive Disorder (MDD) after 24 weeks of treatment.
- Trial name
- NCT01148472
- Testing
- Escitalopram, Duloxetine
- Volunteers
- 294 people
- Sponsor
- H. Lundbeck A/S